Roivant Sciences (Roivant Sciences) Total Assets : $7,312.7 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Roivant Sciences Total Assets?

Roivant Sciences's Total Assets for the quarter that ended in Dec. 2023 was $7,312.7 Mil.

During the past 12 months, Roivant Sciences's average Total Assets Growth Rate was -5.00% per year.

Total Assets is connected with ROA %. Roivant Sciences's annualized ROA % for the quarter that ended in Dec. 2023 was 434.72%. Total Assets is also linked to Revenue through Asset Turnover. Roivant Sciences's Asset Turnover for the quarter that ended in Dec. 2023 was 0.01.

Roivant Sciences Total Assets Historical Data

The historical data trend for Roivant Sciences's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences Total Assets Chart

Roivant Sciences Annual Data

Trend

Mar21

Mar22

Mar23

Total Assets

2,589.69

2,585.13

2,389.60

Roivant Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial										2,202.96	2,389.60	2,136.65	2,065.54	7,312.68

Roivant Sciences Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Roivant Sciences's Total Assets for the fiscal year that ended in Mar. 2023 is calculated as

Total Assets	=	Total Equity (A: Mar. 2023 )	+	Total Liabilities (A: Mar. 2023 )
	=	1607.587	+	782.017
	=	2,389.6

Roivant Sciences's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	6584.582	+	728.097
	=	7,312.7

Roivant Sciences (NAS:ROIV) Total Assets Explanation

Total Assets is connected with ROA %.

Roivant Sciences's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	20384.736	/	( (2065.543	+	7312.679)	/ 2 )
	=	20384.736	/	4689.111
	=	434.72 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Roivant Sciences's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	37.14	/	( (2065.543	+	7312.679)	/ 2 )
=	37.14	/	4689.111
=	0.01

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Roivant Sciences Total Assets Related Terms

Thank you for viewing the detailed overview of Roivant Sciences's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Roivant Sciences (Roivant Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (NAS:ROIV) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

87S:Germany

Address

50 Broadway, 7th Floor, London, GBR, SW1H 0BD

Website

https://www.roivant.com

Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.

Executives

Eric Venker	officer: President & COO	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Keith S Manchester	director	C/O ROIVANT SCIENCES LTD., 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FL, LONDON X0 SW1Y 4L
Daniel Allen Gold	director	6720 VIA AUSTI PARKWAY, SUITE 450, LAS VEGAS NV 89119
Qvt Financial Lp	10 percent owner, other: Director by Deputization	888 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10106
Svf Investments (uk) Ltd	10 percent owner	69 GROSVENOR STREET, LONDON X0 W1K3JP
Rakhi Kumar	officer: Chief Accounting Officer	C/O NEUROPACE INC, 455 N BERNARDO AVENUE, MOUNTAIN VIEW CA 94043
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Performance Llc	10 percent owner	55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Sumitomo Chemical Co., Ltd.	10 percent owner	7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Softbank Vision Fund L.p.	10 percent owner	AZTEC GROUP HOUSE, 11-15 SEATON PLACE, ST HELIER Y9 JE4 0QH
Meghan Fitzgerald	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Richard Pulik	officer: CFO	SUITE 1, 3RD FLOOR, 11-12 ST. JAMES'S SQUARE, LONDON X0 SW1Y 4LB
Vivek Ramaswamy	director	C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Dexcel Pharma Technologies Ltd.	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 3060000